156 related articles for article (PubMed ID: 6403673)
1. [Sodium valproate: a hyperammonemic drug. Study in the epileptic and healthy volunteer].
Marescaux C; Warter JM; Laroye M; Rumbach L; Micheletti G; Koehl C; Imler M; Kurtz D
J Neurol Sci; 1983 Feb; 58(2):195-209. PubMed ID: 6403673
[TBL] [Abstract][Full Text] [Related]
2. Adaptation of hepatic ammonia metabolism after chronic valproate administration in epileptics treated with phenytoin.
Marescaux C; Warter JM; Brandt C; Rumbach L; Micheletti G; Chabrier G; Imler M
Eur Neurol; 1985; 24(3):191-5. PubMed ID: 3922765
[TBL] [Abstract][Full Text] [Related]
3. [Role of hyperammonemia in stuporous states induced by sodium valproate].
Warter JM; Marescaux C; Rumbach L; Micheletti G; Chabrier G; Koehl C; Imler M; Collard M
Rev Neurol (Paris); 1983; 139(12):753-7. PubMed ID: 6420866
[TBL] [Abstract][Full Text] [Related]
4. Hyperammonemia following intravenous valproate loading.
DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
[TBL] [Abstract][Full Text] [Related]
5. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
Hamed SA; Abdella MM
Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
[TBL] [Abstract][Full Text] [Related]
6. [Hyperammonemia in valproate therapy in children and adolescents].
Laub MC
Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
[TBL] [Abstract][Full Text] [Related]
7. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction.
Zaret BS; Beckner RR; Marini AM; Wagle W; Passarelli C
Neurology; 1982 Feb; 32(2):206-8. PubMed ID: 6798491
[TBL] [Abstract][Full Text] [Related]
8. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
Tseng YL; Huang CR; Lin CH; Lu YT; Lu CH; Chen NC; Chang CC; Chang WN; Chuang YC
Medicine (Baltimore); 2014 Sep; 93(11):e66. PubMed ID: 25192484
[TBL] [Abstract][Full Text] [Related]
10. Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine.
Gidal BE; Inglese CM; Meyer JF; Pitterle ME; Antonopolous J; Rust RS
Pediatr Neurol; 1997 May; 16(4):301-5. PubMed ID: 9258962
[TBL] [Abstract][Full Text] [Related]
11. Valproate acute administration, EEG epileptic abnormalities, and ammonemia.
Sannita WG
Neurology; 1992 Oct; 42(10):2003-5. PubMed ID: 1407583
[TBL] [Abstract][Full Text] [Related]
12. [The decreased level of plasma carnitine in patients with epilepsy].
Belousova ED
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):106-110. PubMed ID: 28745680
[TBL] [Abstract][Full Text] [Related]
13. Stuporous episodes during treatment with sodium valproate: report of seven cases.
Marescaux C; Warter JM; Micheletti G; Rumbach L; Coquillat G; Kurtz D
Epilepsia; 1982 Jun; 23(3):297-305. PubMed ID: 6806087
[TBL] [Abstract][Full Text] [Related]
14. Blood ammonia level during valproic acid therapy.
Kugoh T; Yamamoto M; Hosokawa K
Jpn J Psychiatry Neurol; 1986 Dec; 40(4):663-8. PubMed ID: 3110472
[TBL] [Abstract][Full Text] [Related]
15. Valproate-induced coma: case report and literature review.
Duarte J; Macias S; Coria F; Fernandez E; Clavería LE
Ann Pharmacother; 1993 May; 27(5):582-3. PubMed ID: 8347908
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.
Yamamoto Y; Takahashi Y; Suzuki E; Mishima N; Inoue K; Itoh K; Kagawa Y; Inoue Y
Epilepsy Res; 2012 Sep; 101(3):202-9. PubMed ID: 22542569
[TBL] [Abstract][Full Text] [Related]
17. Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE)--a study from tertiary care referral university hospital, north India.
Mehndiratta MM; Mehndiratta P; Phul P; Garg S
J Pak Med Assoc; 2008 Nov; 58(11):627-31. PubMed ID: 19024136
[TBL] [Abstract][Full Text] [Related]
18. Valproate-induced epileptic tonic status.
Capocchi G; Balducci A; Cecconi M; Pelli MA; Picchiarelli A; Silvestrelli G; Zampolini M
Seizure; 1998 Jun; 7(3):237-41. PubMed ID: 9700838
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for hyperammonemia in pediatric patients with epilepsy.
Yamamoto Y; Takahashi Y; Imai K; Mishima N; Yazawa R; Inoue K; Itoh K; Kagawa Y; Inoue Y
Epilepsia; 2013 Jun; 54(6):983-9. PubMed ID: 23409971
[TBL] [Abstract][Full Text] [Related]
20. Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy.
Kwack DW; Kim DW
Clin Neurol Neurosurg; 2023 Oct; 233():107962. PubMed ID: 37717359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
